Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.King says FDA endorses new Skelaxin label
The new labeling includes revised “Precautions” and “Clinical Pharmacology: Pharmacokinetics” sections. Skelaxin is indicated as an adjunct to rest, physical therapy, and other measures for the relief of
The new labeling includes revised “Precautions” and “Clinical Pharmacology: Pharmacokinetics” sections. Skelaxin is indicated as an adjunct to rest, physical therapy, and other measures for the relief of
A separate but related evaluation license agreement has been entered into between University of California, San Diego (UCSD) Office of Technology Transfer and Intellectual Property Services and Medarex
According to Nastech, P&G discussed performing an additional clinical study not included in the original agreement. Subsequently a contract amendment was executed and the $15 million in payments
The study will further evaluate the safety and efficacy of P1A administered in combination with Ampicillin in preventing the damage to the intestinal microflora caused by the residual
As previously reported, Abbott commenced a tender offer for all of the outstanding shares of Kos common stock for $78.00 per share or $3.7 billion in cash. The
Curaxin CBLC102 has been used in the past to treat malaria and has demonstrated efficacy in vitro, in animal models, and in live tumors removed from patients. Initial
The contract will fund AVI’s development of antisense therapeutics to treat the effects of ebola, marburg and junin hemorrhagic viruses, which are seen as biological warfare and bioterrorism
Preliminary data received did confirm that the drug is dose responsive, produces a statistically significant reduction in bad (LDL) cholesterol and has maintained an excellent safety profile. However,
Avandia (rosiglitazone) reduced the risk of failure by 32% compared to metformin and 63% compared to glyburide at five years. Rosiglitazone was also more effective than metformin or
The phase III trials investigated the efficacy and safety of oral lacosamide as adjunctive therapy in adults with uncontrolled partial seizures. The percent reduction in seizure frequency over